Primary Hyperoxaluria Type 3 (PH3)
1 clinical trials · Condition
◉ Watch Primary Hyperoxaluria Type 3 (PH3)
| Record | Firm | Date |
|---|---|---|
| Long Term Extension Study in Patients With Primary Hyperoxaluria (NCT04042402) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2019-07-09 |
Track Primary Hyperoxaluria Type 3 (PH3) automatically
Every clearance here is in the API, with alerts when new ones post.